[Sweats] [Sweats]_老虎社区_美港股上老虎

Begreen
2021-09-03

[Sweats] [Sweats]

Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment

Forte Biosciences announces that it will not continue to advance the development of its atopic derma

Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":815989146,"tweetId":"815989146","gmtCreate":1630635320585,"gmtModify":1632469089903,"author":{"id":3586230033668947,"idStr":"3586230033668947","authorId":3586230033668947,"authorIdStr":"3586230033668947","name":"Begreen","avatar":"https://static.tigerbbs.com/ea08d58edd58086405f2b617c28993c8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Sweats]&nbsp;</span><span>[Sweats]&nbsp;</span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Sweats]&nbsp;</span><span>[Sweats]&nbsp;</span><br></p></body></html>","text":"[Sweats] [Sweats]","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/815989146","repostId":1186835624,"repostType":4,"repost":{"id":"1186835624","kind":"news","pubTimestamp":1630625981,"share":"https://www.laohu8.com/m/news/1186835624?lang=&edition=full","pubTime":"2021-09-03 07:39","market":"us","language":"en","title":"Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186835624","media":"seekingalpha","summary":"Forte Biosciences announces that it will not continue to advance the development of its atopic derma","content":"<p>Forte Biosciences&nbsp;announces that it&nbsp;will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.</p>\n<p>Shares slide nearly&nbsp;82%&nbsp;post market.</p>\n<p><img src=\"https://static.tigerbbs.com/ba305cccf4317784780adcba0d37993e\" tg-width=\"1020\" tg-height=\"522\" width=\"100%\" height=\"auto\"></p>\n<p>In the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.</p>\n<p>\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.</p>\n<p>Forte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Forte Biosciences' shares fall 82% after scrapping development of FB-401 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nForte Biosciences' shares fall 82% after scrapping development of FB-401 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-03 07:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn ...</p>\n\n<a href=\"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FBRX":"Forte BioSciences Inc"},"source_url":"https://seekingalpha.com/news/3736993-forte-biosciences-shares-fall-12-after-scrapping-development-of-fb-401-treatment","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1186835624","content_text":"Forte Biosciences announces that it will not continue to advance the development of its atopic dermatitis treatment FB-401 following mid-stage trial results.\nShares slide nearly 82% post market.\n\nIn the phase 2 study, the drug failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI), the company said.\n\"The topline data is disappointing and we will continue to analyze the data; however, given this readout we will not continue to advance FB-401,\" CEO Paul Wagner said.\nForte Biosciences previously reported that it had cash and cash equivalents of $50.8M as of June 30, 2021.","news_type":1},"isVote":1,"tweetType":1,"viewCount":202,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":16,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}